As of mid-2025 we are co-developing a full product line with customers through R&D, trial‑production, iteration and sample‑delivery. We frame this as expanding into bionic‑robot electromechanical actuators, leveraging motor‑manufacturing expertise to aim for lighter, smaller, higher‑precision units. It is not mass production, carries no separately disclosed revenue line, names no robot customer and is not a reported segment. Filings use only the generic term “electromechanical actuators.”